<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03201887</url>
  </required_header>
  <id_info>
    <org_study_id>Tasmc16ys0ctil</org_study_id>
    <nct_id>NCT03201887</nct_id>
  </id_info>
  <brief_title>Detecting Malingering Detection Using Eye Movements and Response Time (MDER)</brief_title>
  <official_title>Detecting Malingering Detection Using Eye Movements and Response Time</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Loewenstein Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ariel University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Loewenstein Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Performance Validity Tests (PVTs) are widely used for the detection of sub-optimal effort and&#xD;
      malingering in neuropsychological assessments. Threats to their validity however likely to&#xD;
      intensify with time (e.g., information available on the web or from legal representatives)&#xD;
      and may lead to a decline in their ability to differentiate between malingerers and&#xD;
      non-malingerers. Eye movements and response time (RT) are less obvious outcome measures and&#xD;
      under less conscious control than more conventional PVT indices (e.g., accuracy). They are&#xD;
      therefore promising measures that can aid in detecting malingering when used in conjunction&#xD;
      with more conventional PVT indices. The Word Memory Test (WMT) is a widely used PVT in&#xD;
      neuropsychological evaluations. As part of the proposed study, TBI patients, chronic pain&#xD;
      patients and healthy adults (60 in each group) will be randomly divided to one of two&#xD;
      conditions; optimal effort or sub-optimal effort (participants will be asked to play a TBI&#xD;
      patient who wishes to present himself as having cognitive deficits or exaggerate existing&#xD;
      cognitive deficits). The proposed study will improve the WMT's efficacy in detection of&#xD;
      sub-optimal effort in neuropsychological evaluations and therefore protect its validity from&#xD;
      future threats. In addition, the proposed study will provide us with better understanding of&#xD;
      the effect of TBI on eye movements and RTs in general.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Same as in the brief summary&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">July 1, 2017</start_date>
  <completion_date type="Anticipated">January 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Eye Movements</measure>
    <time_frame>1 month</time_frame>
    <description>Eye tracking used to evaluate eye behavior.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Traumatic Brain Damage</condition>
  <condition>Chronic Pain</condition>
  <arm_group>
    <arm_group_label>Sub-optimal Traumatic Brain Injury</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sub-optimal effort</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sub-optimal effort Chronic pain</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sub-optimal effort</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Traumatic Brain Injury</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>optimal effort</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chronic pain</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>optimal effort</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Sub-optimal effort</intervention_name>
    <description>Participants will be asked to play a patient who wishes to present himself as having cognitive deficits or exaggerate existing cognitive deficits</description>
    <arm_group_label>Sub-optimal Traumatic Brain Injury</arm_group_label>
    <arm_group_label>Sub-optimal effort Chronic pain</arm_group_label>
    <other_name>Simulation condition</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>optimal effort</intervention_name>
    <description>Participants will be asked to perform tasks to the best of their abilities.</description>
    <arm_group_label>Sub-optimal Traumatic Brain Injury</arm_group_label>
    <arm_group_label>Sub-optimal effort Chronic pain</arm_group_label>
    <other_name>control condition</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria for all participants:&#xD;
&#xD;
          -  Adult (18-65) female and males.&#xD;
&#xD;
          -  Signed informed consent form.&#xD;
&#xD;
        Inclusion criteria for TBI group:&#xD;
&#xD;
          -  TBI of at least mild severity, as operationalized by Post traumatic amnesia (PTA) &lt; 24&#xD;
             hours&#xD;
&#xD;
          -  Glasgow coma scale (GCS) of 13-15&#xD;
&#xD;
          -  Loss of consciousness (LOC) of 30 minutes or less.&#xD;
&#xD;
        Inclusion criteria for chronic pain patients:&#xD;
&#xD;
        â€¢ Pain without apparent biological value that has persisted beyond three months. This will&#xD;
        be based on the participant self-report, electronic medical records and consultation with&#xD;
        treating physician.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - Exclusion criteria for all participants:&#xD;
&#xD;
          -  Any current eye impairment (e.g., limited visual field, nystagmus, astigmatism&#xD;
             [cylinder], strabismus or any other impairment specified by the participant), past&#xD;
             strabismus, and refractive surgery.&#xD;
&#xD;
          -  Significant past neurological disorder/s and/or neurosurgery (special emphasis will be&#xD;
             put on any language impairment such as aphasia).&#xD;
&#xD;
          -  Significant developmental disorders (e.g., learning disabilities such as dyslexia).&#xD;
             (d)&#xD;
&#xD;
          -  Significant past or present psychiatric disorders (as evident, for example, in&#xD;
             psychiatric inpatient hospitalization and past suicide attempts).&#xD;
&#xD;
          -  Exclusion according to the last three articles (a-c) will be decided by a joint&#xD;
             consultation of the research team.&#xD;
&#xD;
          -  Exclusion criteria for TBI patients and healthy adults:&#xD;
&#xD;
          -  Any condition of chronic pain (see criteria in the inclusion for the chronic pain&#xD;
             group).&#xD;
&#xD;
          -  Exclusion criteria for chronic pain patients and health adults:&#xD;
&#xD;
          -  Significant current neurological disorder/s (special emphasis will be put on any&#xD;
             language impairment such as aphasia) as decided by a joint consultation of the&#xD;
             research team.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Moti Ratmansky, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Loewenstein Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Moti Ratmansky, MD</last_name>
    <phone>972-9-7709140</phone>
    <email>MottiR@clalit.org.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yoram Braw, PHD</last_name>
    <phone>972-54-8132604</phone>
    <email>yoramb@ariel.ac.il</email>
  </overall_contact_backup>
  <verification_date>January 2017</verification_date>
  <study_first_submitted>January 17, 2017</study_first_submitted>
  <study_first_submitted_qc>June 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 28, 2017</study_first_posted>
  <last_update_submitted>June 26, 2017</last_update_submitted>
  <last_update_submitted_qc>June 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Brain Injuries, Traumatic</mesh_term>
    <mesh_term>Chronic Pain</mesh_term>
    <mesh_term>Malingering</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>We do not plan to share IPD</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

